ADC Therapeutics Ownership | Who Owns ADC Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

ADC Therapeutics Ownership Summary


ADC Therapeutics is owned by 2.14% institutional investors, 14.04% insiders, and 83.82% retail investors. Redmile group is the largest institutional shareholder, holding 13.77% of ADCT shares. Biotech Growth Ord is the top mutual fund, with 1.89% of its assets in ADC Therapeutics shares.

ADCT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockADC Therapeutics2.14%14.04%83.82%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Redmile group15.67M13.77%$62.67M
Point72 asset management8.14M7.15%$32.54M
Prosight management, lp7.47M6.57%$29.89M
Orbimed advisors5.91M5.19%$23.63M
Blackrock3.55M4.31%$11.23M
Blackrock funding, inc. /de4.51M3.97%$18.05M
Morgan stanley3.67M3.23%$14.68M
Nantahala capital management2.27M1.99%$9.07M
Bank of america corp /de/1.22M1.47%$3.84M
Goldman sachs group1.59M1.40%$6.38M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Vantage consulting group683.00K24.36%$2.73M
Prosight management, lp7.47M6.97%$29.89M
Redmile group15.67M6.10%$62.67M
Lynx1 capital management lp1.33M1.08%$5.30M
Blue owl capital lp733.57K0.91%$2.93M
Orbimed advisors5.91M0.56%$23.63M
Opaleye management682.53K0.39%$2.73M
Heights capital management326.77K0.36%$1.31M
Nantahala capital management2.27M0.31%$9.07M
Platinum investment management1.16M0.30%$4.63M

Top Buyers

HolderShares% AssetsChange
Blackrock3.55M0.00%3.55M
Tcg crossover management1.39M0.27%1.39M
Lynx1 capital management lp1.33M1.08%1.33M
Artal group1.02M0.08%1.02M
Opaleye management682.53K0.39%682.53K

Top Sellers

HolderShares% AssetsChange
Prosight management, lp7.47M6.97%-3.00M
Heights capital management326.77K0.36%-2.51M
Silverarc capital management---1.80M
Siren---1.16M
Adage capital partners gp---1.00M

New Positions

HolderShares% AssetsChangeValue
Blackrock3.55M0.00%3.55M$11.23M
Tcg crossover management1.39M0.27%1.39M$5.56M
Lynx1 capital management lp1.33M1.08%1.33M$5.30M
Artal group1.02M0.08%1.02M$3.22M
Opaleye management682.53K0.39%682.53K$2.73M

Sold Out

HolderChange
Gradient investments-11.00
Federation des caisses desjardins du quebec-20.00
Northwestern mutual wealth management-36.00
Southstate-46.00
Goalvest advisory-50.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202529-67.78%2,438,452-96.43%20.05%10-67.74%7-82.50%
Jun 30, 2025908.43%68,312,25726.51%632.51%31-20.51%4081.82%
Mar 31, 202584-2.33%54,846,273-2.92%511.76%39-20.41%2237.50%
Dec 31, 2024868.86%56,494,2772.93%531.97%49-5.77%1645.45%
Sep 30, 202478-54,783,5375.76%521.33%51-10.53%1183.33%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Biotech Growth Ord2.13M1.89%-
iShares Russell 2000 ETF1.81M1.61%-
Fidelity Small Cap Index726.86K0.65%-94.23K
iShares Russell 2000 Growth ETF628.23K0.56%-
iShares Biotechnology ETF460.15K0.41%-
State St Russell Sm/Mid Cp® Indx NL Cl C401.24K0.40%-
State St Russell Sm/Mid Cp® Indx SL Cl I401.24K0.36%-
Vanguard Russell 2000 ETF344.65K0.31%-24.16K
iShares Russell 2000 Value ETF286.42K0.29%-
State St Russell Sm Cap® Indx SL Cl I305.70K0.27%-

Recent Insider Transactions


DateNameRoleActivityValue
Oct 27, 2025Redmile Group, LLC-Buy-
Jun 11, 2025Redmile Group, LLC-Buy-
Jun 11, 2025Redmile Group, LLC-Buy-
Dec 11, 2024Redmile Group, LLC-Buy$190.50K
Dec 11, 2024Redmile Group, LLC-Buy$114.00K

Insider Transactions Trends


DateBuySell
2025 Q41-
2025 Q22-
2025 Q1--
2024 Q441
2024 Q32-

ADCT Ownership FAQ


Who Owns ADC Therapeutics?

ADC Therapeutics shareholders are primarily institutional investors at 2.14%, followed by 14.04% insiders and 83.82% retail investors. The average institutional ownership in ADC Therapeutics's industry, Biotech Stocks , is 45.24%, which ADC Therapeutics falls below.

Who owns the most shares of ADC Therapeutics?

ADC Therapeutics’s largest shareholders are Redmile group (15.67M shares, 13.77%), Point72 asset management (8.14M shares, 7.15%), and Prosight management, lp (7.47M shares, 6.57%). Together, they hold 27.50% of ADC Therapeutics’s total shares outstanding.

Does Blackrock own ADC Therapeutics?

Yes, BlackRock owns 4.31% of ADC Therapeutics, totaling 3.55M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 11.23M$. In the last quarter, BlackRock increased its holdings by 3.55M shares, a 100.00% change.

Who is ADC Therapeutics’s biggest shareholder by percentage of total assets invested?

Vantage consulting group is ADC Therapeutics’s biggest shareholder by percentage of total assets invested, with 24.36% of its assets in 683K ADC Therapeutics shares, valued at 2.73M$.

Who is the top mutual fund holder of ADC Therapeutics shares?

Biotech Growth Ord is the top mutual fund holder of ADC Therapeutics shares, with 1.89% of its total shares outstanding invested in 2.13M ADC Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools